Fig. 2From: Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseasesRate of decline in forced vital capacity (FVC) (mL/year) over 52 weeks in the primary analysis, in an analysis excluding subjects who took ≥ 1 restricted or prohibited therapy, and in an analysis excluding FVC measurements taken after initiation of restricted or prohibited therapy (in the overall population)Back to article page